This article is more than 5 years old. Information may no longer be current.
Cosentyx shows long-term efficacy in nail, palmoplantar psoriasis
Novel interleukin-17A inhibitor Cosentyx yielded sustained efficacy in nail and palmoplantar psoriasis through more than 2 years of follow-up, according to a press release.
The findings were presented at the International Congress of Psoriasis from Gene to Clinic in London and are from two trials, Gesture and Transfigure.
Gesture included 205 patients with moderate to severe disease who were treated with 150-mg or 300-mg subcutaneous doses of Cosentyx (secukinumab, Novartis). Clinicians used the palmoplantar investigator’s global assessment (ppIGA) and palmoplantar psoriasis area and severity index (ppPASI) to assess results, along with dermatology life quality index and palmoplantar quality of life instrument.
Results from 2.5 years of follow-up showed 59% of patients treated with the 300-mg dose and 53% of those treated with the 150-mg dose experienced clear or almost clear palms and soles as assessed by ppIGA. Improvements were also reported consistently in ppPASI score. No new safety findings emerged.
The double-blind, randomized, placebo-controlled, phase 3b Transfigure study included 198 patients, also with moderate to severe disease. The same dosing regimens as Gesture were used, as well, this time in comparison with placebo.
Outcomes of transfigure showed an improvement of baseline of -63% as assessed by nail psoriasis severity index score in the 150-mg dose group, while those in the 300-mg dose group improved by -73% at 2.5 years. Improvements were also reported for a sustained period of time for the nail assessment in psoriasis and psoriatic arthritis and EQ-5D measures for both dosing regimens through 2.5 years.
Reference:
Disclosure: The authors report no relevant financial disclosures.